Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.48 USD +2.07% Intraday chart for Petros Pharmaceuticals -1.33% +4.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider CI
Top Premarket Gainers MT
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study CI
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status CI
Maxim Initiates Petros Pharma at Buy Rating With $4 Price Target MT
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) CI
Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA CI
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label CI
Top Premarket Decliners MT
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Petros Pharmaceuticals Secures $15 Million Private Placement Financing MT
Petros Pharmaceuticals, Inc. announced that it has received $15 million in funding CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Top Premarket Decliners MT
Wall Street Set to Open Lower, March Retail Sales Fall More Than Expected MT
US Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment Reports MT
Top Premarket Gainers MT
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Petros Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
Petros Pharmaceuticals Declares 10-to-1 Reverse Stock Split, Effective Wednesday MT
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA CI
Earnings Flash (PTPI) PETROS PHARMACEUTICALS Posts Q2 Revenue $4.2M MT
Chart Petros Pharmaceuticals
More charts
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.
Sector
-
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.48 USD
Average target price
4 USD
Spread / Average Target
+170.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Petros Pharmaceuticals - Nasdaq
  4. News Petros Pharmaceuticals
  5. Petros Pharmaceuticals : Earnings Flash (PTPI) PETROS PHARMACEUTICALS Reports Q1 Revenue $4.1M